WELLNEX LIFE ORD
Wellnex Life directors commit $1.5m to current entitlement offer
The directors of diverse consumer healthcare business Wellnex Life (ASX: WNX) have committed to subscribe for a minimum of $1.5 million as part of the company’s current entitlement offer. The offer is part of the company’s growth strategy, which includes a proposed listing on the AIM market of the London Stock Exchange. Funds raised and […]
Wellnex Life secures $14.3m for dual listing on London Stock Exchange
Wellnex Life (ASX: WNX) has secured conditional binding commitments to raise $14.3 million to fund its proposed dual listing on the London Stock Exchange’s (LSE) Alternative Investment Market (AIM) next month. The company has received interest from UK and Australian institutions and sophisticated investors for a non-renounceable pro-rata entitlement offer of one new Wellnex share […]
Wellnex Life raises $9m ahead of proposed London Stock Exchange AIM listing
Healthcare business Wellnex Life (ASX: WNX) has received initial conditional binding commitments of $9 million to support its proposed dual listing on the AIM sub-market of the London Stock Exchange (LSE). After receiving significant interest from UK-based institutions and sophisticated investors, the company launched the 1:1 non-renounceable entitlement offer it had previously announced earlier this […]
Wellnex Life expands global reach with UK market entry and new product approval
Wellnex Life (ASX: WNX) has achieved another breakthrough in its expansion plans with a new market authorisation (MA) for its liquid paracetamol plus caffeine soft gel. The MA comes after Wellnex made a successful submission to Australia’s Therapeutic Goods Administration for the latest addition to its product range. The company had previously been granted MAs […]